FDA issues EUA for more molnupiravir brands, Pfizer submits application for Paxlovid

Six brands of the anti-COVID-19 drug molnupiravir were granted emergency use authorization by the Philippine Food and Drug Administration, FDA director general Dr. Oscar Gutierrez said Monday.

In President Rodrigo Duterte's Talk to the People, Gutierrez said they issued an EUA for the following brands:

• Molnarz (Faberco)
• Molnaflu (Medethix)
• Auxilto (German Quality Pharma)
• Molxvir (Sun Pharma)
• Molnatris (Mykan)
• Molnupiravir Generic (Lloyd Laboratories/Dr. Zen's Research)

Gutierrez said they granted the EUA to local firm Lloyd Laboratories last January 28 for 200 and 400 mg of molnupiravir capsules.

"Malinaw po sa findings ng FDA na may capacity po siyang mag-produce ng molnupiravir capsules under current good manufacturing practice at ang molnupiravir naman ay meets the safety and quality standard as an investigatory COVID-19 drug," he said.

Meanwhile, Gutierrez said Pfizer already applied for an EUA for Paxlovid, its anti-viral therapy pill.

He added that the application is currently undergoing evaluation.

Further, Gutierrez said the FDA will continue to receive and approve compassionate special permit applications within the next three months to augment the supply of investigatory COVID-19 drugs nationwide. -- BAP, GMA News